Gangwon Regional Innovation Platform and Cipherome, Inc. - cooperation in cultivating tomorrow's Healthcare Data Professionals

Gangwon Regional Innovation Platform and Cipherome came together on January 12 for an MOU ceremony, marking their dedication to establishing innovative platforms and organizing events aimed at enhancing education in healthcare data analysis.

https://www.veritas-a.com/news/articleView.html?idxno=491040

Data Science Hackathon made possible with COMPASS in Gangwon, Korea

Over 70 university students applied for this first-ever COMPASS hackathon, held from 1/5 to 1/12. Selected 25 teams (2 students in each team) competed in this hackathon by utilizing Compass and synthetic healthcare datasets provided by Cipherome.

On the last day of the hackathon, all teams were given opportunities to present their analysis results through a poster session. Out of 10 finalist teams, 2 teams were selected to visit Cipherome’s HQ in San Jose, CA as data science interns.

https://www.kwnews.co.kr/page/view/2023121817060863266

SNU Bundang Hospital and Cipherome, Inc. conclude an MOU for cooperation in Personalized Medicine

Cooperation for the Establishment of the Precision Medicine Research Platform at SNUBH Biomedical Research Institute

Seoul National University (SNU) Bundang Hospital Biomedical Research Institute announced that it concluded the MOU on November 15, 2022, to standardize clinical genomic research using Cipherome, Inc.’s precision medicine research platform at the SNU Precision Medicine Center.

Precision Medicine Center, an integral part of the Future Innovation Research Department of Seoul National University Bundang Hospital in supporting our medical staff with genomics education and research support programs, is currently establishing large-scale cohorts based on the hospital’s biobank.

At the signing ceremony on November 15th, Ji-Soo Kim (President & Chief Research Officer of the Biomedical Research Institute of Seoul National University Bundang Hospital), Jee Hyun Kim (Head of the Future Innovation Research Department), Jung Hun Ohn (Director of the Precision Medicine Center), Jinho Kim and Sejoon Lee (professors at the Precision Medicine Center), Ilsong Lee (CEO of Cipherome), Min Kim (CTO of Cipherome), and others commented on the future direction of personalized medicine using clinical genomic factors.

Because of the high need for tools to organize, vet, and perform genomic and clinical data research and the lack of accessible tools for clinical researchers, Cipherome has commercialized its data analysis development system, the Compass Platform, to empower clinical researchers to carry out complex data science tasks—from statistical analysis to machine learning training—on genomic and clinical data efficiently and rapidly.  A primary goal is to shorten the time to results of population-scale extrapolations using UK BioBank data.

Ji-Soo Kim, the president of Seoul National University Bundang Hospital Biomedical Research Institute, stated: “Through this MOU with Cipherome, we will actively support the precision medicine R&D based on clinical and genomic big data. We will continue to strengthen our research capability to take the lead of the precision medicine in the global market.”

Ilsong Lee, the CEO of Cipherome also said: “Our cooperation with Seoul National University Bundang Hospital Biomedical Research Institute is central to achieving impact and adoption of clinical genomics since the Institute plays a key role in the advancement of the medical industry through its R&D on highly advanced, innovative medical technology. We hope that this MOU will contribute to improving the precision medicine research competitiveness and capability of Seoul National University Bundang Hospital.”

The Korean press release can be found here: http://www.bosa.co.kr/news/articleView.html?idxno=2185045

Please direct questions to: info@cipherome.com

About Cipherome

Cipherome is an AI and bioinformatics company focused on personalizing medications to limit ADRs using patented technology. Our team brings extensive experience in medicine, drug development, bioinformatics, AI, and award-winning product development to address a $100B+ problem in healthcare: variability of drug response.

The Xentinel® Compass Platform can analyze large-scale genomic and clinical data in a fast and easy manner. Using its unique modularized architecture, the platform is highly configurable and extensible to extract and convert data from various clinic genomic big data sources, including UK BioBank. As an end-to-end analysis platform which provides comprehensive functionalities in cohort selection, feature engineering, exploratory data analysis, statistical analysis, machine learning, and visualization, this platform enhances researchers’ accessibility to biobank data and provides the most efficient path to data insight. While the platform has many applications, its current primary focus is on maximizing the efficiency of genome-clinical data analysis and accelerating new drug development and treatment research. Currently, its applications are being promoted through cooperation with university hospitals and research organizations as well as global pharmaceutical companies. Cipherome’s platform is in use at point of care to personalize treatment for post heart attack patients and diabetic induced peripheral arterial disease in South Texas, Illinois, and New Jersey.

Cipherome, Inc. is selected as a Finalist in the prestigious American Heart Association Competition

San Jose, California, November 1, 2022 – Cipherome, Inc. (“Cipherome”), a Silicon Valley-based, genomic bioinformatics start-up, is excited to announce that we’ve been selected a finalist at the AHA’s Health Technology & Innovation Health Tech Competition.

“We believe that personalized medicine is a key component of addressing medical equity issues, and we are very excited to be recognized with such a prestigious invitation by the AHA,” said Jane Chiang, M.D. Chief Medical Officer at Cipherome.

Please joins us at the AHA Scientific Session in Chicago (11/5 - 11/7). #AHA22

https://newsroom.heart.org/news/healthcare-and-tech-leaders-evaluate-entrepreneurial-ideas-in-live-innovation-competition

About Cipherome

Cipherome was founded on the belief that each individual deserves the best medicine. Cipherome’s proprietary clinical genomics platform leverages explainable artificial intelligence and machine learning to work toward reducing adverse drug reactions and improving outcomes by personalizing drug treatment. Cipherome is headquartered in San Jose, California

Yongin Severance Opens 'UK Biobank Big Data Platform Symposium' with Cipherome

Yonsei University College of Medicine Yongin Severance Hospital held the 'UK Biobank Big Data Analysis Platform Construction Kickoff Symposium' with Cipherome, Inc., a US Silicon Valley bio-venture company on September 16th. 

UK Biobank is a biobank that has registered about 500,000 biomedical databases and is conducting cutting-edge gene discovery research. This symposium is an event to announce the start of the project after the 'Precision Medicine Platform Construction Project' was signed between Yongin Severance Hospital and Cipherome in February. Yongin Severance Hospital President Kim Eun-kyung, Digital Medical Industry Center Director Park Jin-young, Cipherome CEO Ilsong Lee, Vice President Yong-ho Yong, and CTO Min Kim attended the symposium to establish a big data analysis platform with the goal of realizing precision medicine and strengthening the research capabilities of Yongin Severance Hospital faculty members. Future cooperation plans were discussed. The announcement held on this day was Yongin Severance Hospital-Cipherome MOU and UK Biobank.

Yongin Severance Hospital and Cipherome plan to build a big data precision medicine platform. The collaboration will use Cipherome’s precision medicine platform (Min Kim CTO) and big data analysis (Professor Seong-ah Bae, Department of Cardiology) and will focus on UK Biobank data for research in internal medicine (Professor Seong-su Ahn, Department of Rheumatology) and in surgery (Professor Kim Wan-gi, Thoracic Surgery).

“Based on the research capabilities of both institutions and genomics, big data and machine learning analysis technologies, we will accelerate the innovation of next-generation medical systems and the development of the precision medicine industry,” said Kim Eun-kyung, head of the hospital. “I hope it will be an opportunity to do so,” he said.

In addition, Kim Eun-kyung announced that he plans to strengthen the realization of precision medicine based on big data of integrated clinical-genomic information and related research capabilities.

Update to CARES2 Pilot Study

The CARES2 study completed recruitment in June 2022, and we share an important observation: 1 in 4 study participants were impaired metabolizers. This finding is approximately twice the reported prevalence of CYP2C19*2 polymorphisms in subjects with Latino ancestry per CPIC.

This means that the well known higher 1-year stroke, MI and cardiovascular death outcome for cardiovascular patients of Latinx ancestry is due in part to a higher variability of anti-platelet treatment efficacy from these impaired metabolizers.

“This study points to the potential benefit to alert physicians of an inherited metabolic impairment relevant to improving their patients’ outcome,” said José Estabil ScM, Cipherome Chief Business Officer.

The study’s interim read-out, “Evaluating Pharmacogenomic Variants for Therapeutics (CARES2),” was presented on June 30th at Precision Medicine West Conference by a team from the Heart Institute at DHR Health in McAllen, TX and Cipherome in San Jose, CA.

To learn more about the CARES2 study at Precision Medicine World Conference, follow the link below: https://www.pmwcintl.com/session/pharmacogenomics-track_2022sv

To find about the CARES2 Study please visit: NCT04702113

Cipherome, Inc. is a venture-backed AI/genomics company personalizing medicine to limit adverse drug reactions.

Cipherome, Inc. joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

American Heart Association consortium advances development of evidence-based health tech solutions

San Jose, California, March 31, 2022 – Cipherome, Inc. (“Cipherome”), a Silicon Valley-based, genomic bioinformatics start-up, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions.

The Innovators’ Network is a consortium that connects entrepreneurs, providers, researchers and payers. Innovators’ Network members also have access to the Association’s digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.

“The Center aims to advance the rapid, efficient, and effective development of healthcare technology,” said Eric Peterson, M.D., M.P.H., Vice Provost and Senior Associate Dean for Clinical Research at University of Texas Southwestern and volunteer chair of the American Heart Association’s Health Tech Advisory Group for the Center. “It’s incredibly encouraging to see Cipherome leveraging this consortium to broaden and deepen their engagement in this arena.”

“We believe that personalized medicine is a key component of addressing medical equity issues, and we are very excited to join the network with a goal of clinical adoption of personalized medicines for cardiovascular patients,” said Jane Chiang, M.D. Chief Medical Officer at Cipherome.

About Cipherome

Cipherome joins the Innovators’ Network bringing with them a personalized medicine product - Xentinel® Lighthouse – with a goal to become the standard of care for patients undergoing percutaneous coronary interventions (PCI).

Cipherome was founded on the belief that each individual deserves the best medicine. Cipherome’s proprietary clinical genomics platform leverages explainable artificial intelligence and machine learning to work toward reducing adverse drug reactions and improving outcomes by personalizing drug treatment. Cipherome is headquartered in San Jose, California. For more information, visit our website at www.cipherome.com.

Yongin Severance Hospital and Cipherome sign an agreement to establish a precision medicine platform program

Yonsei University College of Medicine Yongin Severance Hospital announced that it signed a business agreement with Cipherome, a Silicon Valley biotech company, to build a precision medicine platform.

Precision medicine is medicine that provides prevention and treatment of diseases by collecting and analyzing comprehensive data such as individual genomic information, biological characteristics, lifestyle, environment, and medical history. It is a field that is receiving great attention around the world in that it can implement customized medical care that takes into account individual characteristics.

At the signing ceremony, Yongin Severance Hospital agreed to conduct joint research with the goal of securing a competitive advantage in the digital healthcare field with Cipherome, realizing precision medicine based on big data based on clinical-genomic integrated information, and securing related research capabilities. 

The cooperation between the two institutions, which both have strengths in advanced medicine, is expected to create great synergy effect in basic research and development, big data genome analysis, and machine learning-based prediction infrastructure. In particular, Yongin Severance Hospital plans to build a precision medicine platform based on the signing of the agreement, apply it to clinical and research fields, and strengthen its precision medicine capabilities based on this.

Director Choi Dong-hoon said, “Based on the research capabilities of both institutions, genome and machine learning analysis technologies, we will accelerate the development of the next-generation medical system innovation and precision medicine industry. We will implement cutting-edge smart medical care.”

Meanwhile, Yongin Severance Hospital won the “Korea Digital Management Innovation Awards Prime Minister's Award” for introducing an advanced smart hospital model, such as establishing a 5G communication network for the first time in a domestic medical institution. The Ministry of Health and Welfare has been designated as a “high-tech regenerative medical institution.” 

Cipherome has commercialized “genomic analysis-based drug suitability prediction algorithm service” based on genome and big data analysis technology and developed a personalized genome analysis service through next-generation sequencing analysis and machine learning-based prediction. 

용인세브란스병원, 싸이퍼롬과 정밀의학 플랫폼 구축사업 협약

연세대학교 의과대학 용인세브란스병원이 지난달 23일 5층 대회의실에서 미국 실리콘밸리 바이오벤처 기업 싸이퍼롬(Cipherome)과 정밀의학 플랫폼 구축사업 업무협약을 체결했다고 3일 밝혔다.

정밀의학은 개인의 유전체 정보, 생물학적 특성, 생활 습관, 환경, 병력 등의 종합적인 데이터를 수집하고 분석해 질병의 예방과 치료를 제공하는 의학이다. 개개인의 특성을 고려한 맞춤형 의료를 구현할 수 있다는 점에서 전 세계적으로 큰 주목을 받고 있는 분야다.

협약식에서 용인세브란스병원은 싸이퍼롬과 디지털 헬스케어 분야의 경쟁우위 확보와 임상-유전체 통합 정보 빅데이터 기반 정밀의학 구현 및 관련 연구 역량 확보를 목표로 공동 연구를 진행해 나가기로 협의했다. 

첨단 의료에 강점을 지닌 양 기관의 협력은 기초 연구개발, 빅데이터 유전체 분석, 머신러닝 기반 예측 인프라 등에서 큰 시너지 효과를 낼 것으로 기대된다. 특히, 용인세브란스병원은 협약 체결을 바탕으로 정밀의학 플랫폼을 구축해 임상 및 연구 분야에 적용하고 이를 기반으로 정밀의학 역량을 강화해 나갈 예정이다.

최동훈 병원장은 “양 기관의 연구 역량과 유전체, 머신러닝 분석 기술을 바탕으로 차세대 의료 시스템 혁신과 정밀의학 산업의 발전을 가속화하겠다”며 “이를 통해 환자 개개인의 특성을 고려해 치료 효과를 극대화한 환자 맞춤형 첨단 스마트 의료를 구현해 나가겠다”고 밝혔다.

한편, 용인세브란스병원은 국내 의료기관 최초로 5G 통신망을 구축하는 등 선진적인 스마트병원 모델을 선보여 ‘대한민국 디지털 경영혁신대상 국무총리상’을 수상한 바 있으며, 세포·유전자·조직공학 치료 기술 연구 역량을 인정받아 ‘보건복지부 첨단재생의료실시기관’으로 지정됐다. 

싸이퍼롬은 유전체·빅데이터 분석 기술을 기반으로 ‘유전체 분석 기반 약물 적합성 예측 알고리즘 서비스’를 상용화했으며 차세대 염기서열 분석 및 머신러닝 기반 예측을 통해 개인 맞춤 유전체 분석 서비스를 개발했다.

New Miami-based initiative AccurePCI to catalyze personalized medicine innovation in Miami-Dade

Global CoCreation Lab and Cipherome partnership to address growing health equity gap with innovative genomics technology

MIAMI—AccurePCI, a project partnership of Miami foundation Global CoCreation Lab and Silicon Valley-based Cipherome announced today, will bring new tools to the region’s medical community for personalizing treatment of heart disease patients, including populations historically underrepresented in medical research.  

“Miami’s health security and economic resilience require us to innovate, to overcome chronic challenges and stay ahead of emerging threats,” remarks Leland Salomon, Deputy Director, Department of Regulatory and Economic Resources at Miami-Dade County. “The AccurePCI project represents a growing wave of innovation in Miami, inspiring new technology and businesses right here in our community to meet our most urgent needs.”

A health equity gap has grown between those who participate in clinical development of personalized medicines and devices and those who consume them. While 25% to 42% of FDA-approved drugs have included genomic information on their label over the last five years, less than 1% of Latinos and 5% of African Americans have been included in clinical development of new drugs nationwide and even though they are a larger percentage of medical consumers. This gap can create health vulnerabilities FDA-approved medicines, since issues arise when drugs are approved on homogeneous populations and released for general use in diverse ones, like the US. 

Since people of Latin American, African and Asian ancestry are disproportionately vulnerable to drug-induced complications, this is especially critical in Miami-Dade County.

AccurePCI aims to use clinically-driven results to help healthcare professionals personalize life-saving treatments for each person in the county’s diverse community, and to catalyze growth of a precision medicine businesses using genomics to address the needs of Miami-Dade’s citizens, from sequencing to AI-driven algorithms that personalize drug recommendations for doctors.

“Genomics can be a powerful tool to personalize treatment. Cipherome’s decision to join the AccurePCI project will help catalyze genomic tools to improve health for everyone in Miami-Dade, including traditionally underrepresented populations,” says Alejandro Roman, Executive Director of the Global CoCreation Lab. 

“Cipherome’s Xentinel Lighthouse platform, which AccurePCI will use, was built with clinicians and patients in mind, and it is bilingual by design,” says Ilsong Lee, Cipherome CEO. “By doing this, it helps us reach our goal to help improve health outcomes and reduce costs by personalizing drug treatment.”

With this technology, clinicians can personalize drug prescriptions and share results with patients, improving health outcomes, access, and equity for underrepresented minorities.

“We’re focused now on getting this technology in cardiology caregivers’ hands,” said Roman. “Miami needs it, and we can set a global example for innovation in this area.”

About the Global CoCreation Lab

The Global CoCreation Lab bridges academic research, civic leadership, medicine, and business for community-based healthcare technology innovation and entrepreneurship. Our cocreation ethos and commitment to diverse inclusion in innovation drives more equitable economic and human development. 

About Cipherome, Inc.

Cipherome’s goal is to provide best-in-class precision medicine solutions. Cipherome is a venture-backed company headquartered in San Jose, California, and was founded on the belief that every individual deserves the best medicine. Drugs that work for most of the population may not work for everyone. Serious adverse drug reactions (ADRs) occur in certain individuals, but not in others. These differences may be due to inherited factors. Cipherome’s unique patented platform combines many components, including genetics, to reduce ADRs by personalizing drug treatment.

Contact

Eric Norman
Global CoCreation Lab
enorman@globalcocreationlab.org
617-733-3540

José Estabil 
Cipherome, Inc.
info@cipherome.com
408-243-1460

DHR Health and Cipherome to Pioneer Personalized Medicine Project in Patients Undergoing Percutaneous Coronary Interventions

The First Gene Based Project to be conducted in the Texas Rio Grande Valley

Edinburg, TX (February 8, 2021) – Can a medical tool predict the risk of certain medications based on a patient’s genetics, and, if so, could this information lead to doctors customizing a patient’s drug therapy?  The tool being studied at DHR Health Institute for Research & Development to answer these questions is Cipherome’s Xentinel® Lighthouse, and this pilot study will also evaluate the resulting savings in health-care costs.

After a stroke or heart attack, the standard treatment is Percutaneous Coronary Intervention (PCI), or stent placement. A stent opens blood vessels in the heart that have narrowed due to the buildup of plaque. Following PCI, doctors typically prescribe aspirin and a P2Y12 inhibitor, such as clopidogrel (Plavix), to reduce the risk of stent thrombosis, which is the formation of a blood clot on the surface of the stent. Lighthouse is a support tool that allows physicians to predict how a patient will respond to drug therapies based on that patient’s genetic makeup. Cipherome, Inc. chose South Texas for this pilot project to better understand how the genetic differences in Hispanic/Latino patients relate to the effectiveness and safety of medications used to treat them.

“Most prior studies to anticipate major bleeding caused by this drug therapy have been based on data collected from Caucasian patients, have not been based on a patient’s individual risk profile, and have not been strong predictors of thrombosis risk,” says Dr. Herschl Silberman, a cardiologist at DHR Health and a Clinical Research Scientist, DHR Health Institute for Research & Development. “This lack of effective clinical tools has resulted in high numbers of emergency room visits and patients being readmitted to the hospital with stent thrombosis, bleeding, and other complications.”

In 2019 alone, over 1.5 million patients visited an emergency room or were hospitalized due to unexpected reactions to drug therapies, and 174,000 people in the U.S. lost their lives due to these adverse reactions.  Recent studies show the possibility of an 80-percent reduction in PCI 90-day complications by using a patient’s personalized genetic information.

“Personalized medicine brings great promise to improve outcomes for our patients and we are focused on pioneering innovative practical solutions that can produce better results for our clinicians and patients,” says Dr. Sohail Rao, Executive Vice President, DHR Health and President and CEO of DHR Health Institute of Research and Development. “Our credibility and service to the large Hispanic population in South Texas is the ideal place for our first deployment of clinical decision support systems,” says Ilsong Lee, Cipherome CEO.

This study is open to patients 18 years of age and older who have been prescribed clopidogrel, prasugrel (Effient®), or ticagrelor (Brilinta®) after a PCI with at least one stent placement.  There are two study arms, or groups, one receiving clopidogrel but no genotyping to identify the patient’s genetic makeup and the other receiving genotype-guided therapy. Patients in the study will be evaluated for a period of one year.

###

About DHR Health Institute for Research and Development:

DHR Health Institute for Research & Development is a nonprofit organized under the Federal Internal Revenue Service Code 501(c)(3).  DHR Health Institute for Research and Development leads the way for innovative state-of-the-art clinical research in the Rio Grande Valley. For more information, please call 956-362-2387 or visit our website at www.dhrresearch.org. Join our community @DHRResearch:

About Cipherome, Inc.

Cipherome’s goal is to provide best-in-class precision medicine solutions. Cipherome is venture-backed company headquartered in San Jose, California and founded on the belief that each individual deserves the best medicine. Drugs that work for the majority of the population may not work for everyone. Serious adverse drug reactions (ADRs) occur in certain individuals, but not in others. These differences may be due to inherited factors. Cipherome’s unique patented platform combines many components, including genetics, to reduce ADRs by personalizing drug treatment. For more information, visit our website at www.cipherome.com.